Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.43 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.33 |
| ▸ | CCR7 | P32248 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459467 | 0.88 | CXCR2 (0.37) | CXCR2HTR1BCX3CR1 | |
| SCHEMBL489918 | 0.86 | CXCR2 (0.45) | CXCR2CXCR1HTR1BCX3CR1 | |
| SCHEMBL489866 | 0.80 | CXCR2 (0.65) | CXCR2CXCR1HTR1BCX3CR1 | |
| SCHEMBL4459471 | 0.73 | CXCR2 (0.42) | CXCR2 | |
| SCHEMBL489702 | 0.72 | CXCR2 (0.38) | CXCR2CXCR1HTR1BCX3CR1 | |
| SCHEMBL489701 | 0.72 | CXCR2 (0.38) | CXCR2CXCR1HTR1BCX3CR1 | |
| SCHEMBL490248 | 0.70 | CXCR2 (0.55) | CXCR2CXCR1 | |
| SCHEMBL490347 | 0.70 | CXCR2 (0.51) | CXCR2CXCR1 | |
| SCHEMBL489912 | 0.68 | CXCR2 (0.83) | CXCR2CXCR1HTR1BCX3CR1CCR7 | |
| SCHEMBL489899 | 0.68 | CXCR2 (0.44) | CXCR2CXCR1CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527051-B1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8106063-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-01-31 | — | — | US | disclosed |
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | disclosed |
| US-7582644-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ACKR3, GPR17, CCL11 | CXCR2 38/4885CXCR1 9/4885HTR1B 2017/4885 |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ACKR3, GPR17, CCL11 | CXCR2 38/4885CXCR1 9/4885HTR1B 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.